MASTROMARINO, VITTORIA
 Distribuzione geografica
Continente #
NA - Nord America 1.197
EU - Europa 406
AS - Asia 126
AF - Africa 27
SA - Sud America 7
Totale 1.763
Nazione #
US - Stati Uniti d'America 1.191
IT - Italia 136
AT - Austria 92
IN - India 59
FI - Finlandia 50
CN - Cina 43
DE - Germania 29
TG - Togo 26
BG - Bulgaria 17
UA - Ucraina 17
SE - Svezia 16
FR - Francia 15
IE - Irlanda 11
PK - Pakistan 10
NL - Olanda 9
GB - Regno Unito 8
AR - Argentina 7
CA - Canada 6
TR - Turchia 5
RO - Romania 4
BA - Bosnia-Erzegovina 2
HK - Hong Kong 2
JP - Giappone 2
SG - Singapore 2
IL - Israele 1
IR - Iran 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 1.763
Città #
Fairfield 198
Ashburn 99
Woodbridge 93
Seattle 92
Vienna 76
Houston 75
Wilmington 72
Chandler 67
Cambridge 66
Rome 55
Princeton 30
San Diego 30
Dearborn 29
Ann Arbor 27
Plano 27
Lomé 26
Helsinki 25
San Paolo di Civitate 22
Beijing 20
Lawrence 20
Sofia 17
Millbury 16
Boston 15
New York 15
Dublin 11
Faisalabad 10
Andover 8
Federal 7
Norwalk 7
Shanghai 6
Toronto 6
Istanbul 5
Fasano 4
Jacksonville 4
Kunming 4
San Mateo 4
Washington 4
Fremont 3
Guangzhou 3
Ponte San Nicolò 3
Asheville 2
Augusta 2
Boardman 2
Bremen 2
Cagliari 2
Cesena 2
Giaveno 2
Hefei 2
London 2
Lucca 2
Nanjing 2
Paris 2
Perugia 2
Pune 2
Redmond 2
Rubano 2
Tokyo 2
Bühl 1
Chongqing 1
Columbus 1
Enna 1
Falls Church 1
Fisherabad 1
Formigine 1
Hanoi 1
Harbin 1
Hendon 1
Laurel 1
Linköping 1
Milan 1
Muizenberg 1
Nanning 1
Ningbo 1
Nürnberg 1
Paese 1
Phoenix 1
Pordenone 1
Portici 1
Redwood City 1
Rivalta Di Torino 1
Scunthorpe 1
Tel Aviv 1
Vasto 1
Xian 1
Totale 1.362
Nome #
Restrictive cardiomyopathy and pseudoxanthoma elasticum skin lesions. 96
Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy 91
Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy 87
QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy. time for reappraisal. 79
Erythropoietin and the heart: facts and perspectives. 76
Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy 74
Polypharmacy in Heart Failure Patients 73
Heart failure progression in hypertrophic cardiomyopathy, Possible insights from cardiopulmonary exercise testing 73
Myocardial Repolarization Dispersion and Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy 71
null 68
null 67
The natriuretic peptides system in the pathophysiology of heart failure. From molecular basis to treatment 65
Natriuretic peptides and volume handling in heart failure. The paradigm of a new treatment 64
Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease 61
Simultaneous Takotsubo syndrome in two sisters 60
Reducing Cardiovascular and Cancer Risk. How to Address Global Primary Prevention in Clinical Practice 56
null 56
null 56
null 55
Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease 54
Risk stratification in hypertrophic cardiomyopathy. Insights from genetic analysis and cardiopulmonary exercise testing 54
Genotype in hypertrophic cardiomyopathy: clinical implications 50
Spatial QT dispersion predicts non-sustained ventricula tachycardia and correlates with a confined systo-diastolic dysfunction un hypertrophic cardiomyopathy 49
IGF-1 and atherothrombosis: relevance to pathophysiology and therapy 48
null 47
Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link? What both cardiologist and oncologist should know about novel angiogenesis inhibitors 42
Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome 41
Anemia and heart failure. Is there still a role for erythropoiesis-stimulating agents? 39
Erythropoietin in cardiac disease: effective or harmful? 29
[Role of adherence to chronic drug therapy in patients with cardiovascular disease: an Italian intersocietary consensus document]. 27
Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control 22
Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis 15
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control 13
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 11
Erythropoiesis-stimulating agents in heart failure: Leave it or re-take it? 7
Totale 1.876
Categoria #
all - tutte 4.181
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.181


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019184 0 0 0 0 0 0 0 2 1 42 83 56
2019/2020449 63 14 5 18 43 69 60 53 56 35 18 15
2020/2021112 11 16 12 8 2 8 0 9 15 15 11 5
2021/2022358 3 14 38 7 41 3 10 35 23 18 100 66
2022/2023322 61 80 22 18 33 22 12 15 25 2 22 10
2023/2024224 18 38 9 31 21 62 6 39 0 0 0 0
Totale 1.876